Plesner Torben
Department of Hematology, Vejle Hospital, Institute of Regional Health Science, University of Southern Denmark, Beriderbakken 4 DK, 7100 Vejle, Denmark.
J Clin Med. 2021 Mar 2;10(5):1002. doi: 10.3390/jcm10051002.
A search of the scientific literature for and gives more than 600 results (January 2021), which reflects the interest and activity around this antibody, an interest that was also reflected by the assignment of breakthrough designation for Daratumumab as a treatment for multiple myeloma by FDA in 2013. The high expectations have been supported and met due to a very active clinical development program, and our insight into Daratumumab's modes of action have been expanded by a concomitant, systematic activity of translational research. The scope of this article is to point to some areas where the outcome of treatment with Daratumumab for multiple myeloma may be improved with a focus on areas such as when to initiate treatment with Daratumumab, the use of supportive treatment, duration of therapy and some general thoughts about anti-myeloma treatment as a two-step process involving initial de-bulking followed by reprogramming of the host's immune system and immune-mediated control of myeloma.
在科学文献中搜索[具体药物名称]和[具体药物名称]，得到了600多个结果（2021年1月），这反映了围绕这种抗体的关注度和研究活跃度，这种关注也体现在2013年美国食品药品监督管理局（FDA）将达雷妥尤单抗指定为治疗多发性骨髓瘤的突破性疗法上。由于非常活跃的临床开发项目，这些高期望得到了支持并得以实现，同时，伴随的系统性转化研究活动也扩展了我们对达雷妥尤单抗作用模式的认识。本文的范围是指出一些领域，在这些领域中，针对多发性骨髓瘤使用达雷妥尤单抗治疗的结果可能会得到改善，重点关注的领域包括何时开始使用达雷妥尤单抗治疗、支持性治疗的使用、治疗持续时间，以及关于抗骨髓瘤治疗作为一个两步过程的一些总体思考，该过程包括初始减瘤，随后对宿主免疫系统进行重新编程以及通过免疫介导控制骨髓瘤。
